selected scholarly activity
-
conferences
- Dementia risk among post-menopausal women treated with endocrine therapy for early-stage breast cancer in Ontario, Canada.. Journal of Clinical Oncology. 2020
- Basal biomarkers Nestin and INPP4b accurately identify intrinsic breast cancer subtype and predict benefit from anthracycline vs. non-anthracycline based treatment in the CCTG MA. 5 phase III randomized clinical trial. Modern Pathology. 46-46. 2018
- Increasing the dose density of adjuvant chemotherapy by shortening intervals between courses or by sequential drug administration significantly reduces both disease recurrence and breast cancer mortality: An EBCTCG meta-analysis of 21,000 women in 16 randomised trials. Cancer Research. 2018
- Targeted sequencing in early breast cancer: Identification of novel candidate mutations predictive of anthracycline benefit. Cancer Research. 2018
- Validation that a histone gene signature predicts anthracycline response in early breast cancer. Cancer Research. 2018
- Adjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06). Annals of Oncology. 2017
- Feasibility of routine collection of health state utilities using EQ-5D in a breast cancer outpatient clinic. Annals of Oncology. 2017
- Abstract P2-09-14: Association between BMI and residual estradiol levels in post-menopausal women using adjuvant letrozole: Results of a prospective study. Cancer Research. 2017
- Abstract P6-09-30: Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with Trastuzumab. Cancer Research. 2017
- Abstract PD7-07: Discovery of molecular predictors of late breast cancer specific events (BCSE) in ER+, node+ breast cancer – new transcriptome expression whole gene analysis of the phase III adjuvant trial SWOG S8814. Cancer Research. 2017
- Effects of endocrine therapy on cognitive functioning in women treated for breast cancer: A meta-analysis. Psycho-Oncology. 68-68. 2017
- Prospective evaluation of the impact of the 21-gene recurrence score® assay on adjuvant treatment decisions for women with node-positive breast cancer in Ontario, Canada. Annals of Oncology. vi54-vi54. 2016
- A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.. Journal of Clinical Oncology. 2016
- Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer.. Journal of Clinical Oncology. 2016
- Anthracycline-induced cardiotoxicity in patients with early stage breast cancer: The Canadian cancer trials group (NCIC CTG) MA.21 experience.. Journal of Clinical Oncology. 1016-1016. 2016
- Abstract P2-08-01: Prospective trial of endocrine therapy alone in patients with estrogen receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry. Cancer Research. 2016
- Abstract P5-07-01: Successful whole transcriptome analysis of 25-year-old breast tumor samples from the phase III trial SWOG-8814 by next generation sequencing (NGS): Standardized analytical methods for exploratory and validation studies. Cancer Research. 2016
- Abstract P5-12-02: Effect of 5 vs 2.5 mg/day letrozole on residual estrogen levels in post-menopausal women with high BMI - A prospective crossover study. Cancer Research. 2016
- Abstract P5-14-01: A meta-analysis of clinical benefit rates for fulvestrant 500 mg versus alternative therapies for treatment of postmenopausal, estrogen receptor-positive advanced breast cancer. Cancer Research. 2016
- Abstract PD2-01: Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) trial. Cancer Research. 2016
- Abstract PD5-07: The impact of early lapatinib-induced rash on disease-free and overall survival in patients treated within the ALTTO phase III randomized trial. Cancer Research. 2016
- Abstract S3-02: Molecular predictors of outcome on adjuvant CAF plus tamoxifen (T) vs T in postmenopausal patients (pts) with ER+, node+ breast cancer – Transcriptome expression analysis of the phase III trial SWOG-8814. Cancer Research. 2016
- 5BA Prospective trial of endocrine therapy alone in patients with estrogen-receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry. European Journal of Cancer. S714-S714. 2015
- Abstract CT317: Quantitative ultrasound for personalized chemotherapy in locally advanced breast cancer: Clinical trial results. Cancer Research. CT317-CT317. 2015
- Expression of thyroid hormone receptor alpha (THR alpha) isoforms in triple negative breast cancer (TNBC). Journal of Clinical Oncology. 2015
- Hepatitis B virus screening before adjuvant chemotherapy in patients with early stage breast cancer: A cost-effectiveness analysis.. Journal of Clinical Oncology. 6617-6617. 2015
- Abstract P2-05-05: A four gene signature predicts anthracycline benefit: Evidence from the BR9601 and MA5 breast cancer trials. Cancer Research. 2015
- Abstract P6-01-10: Prognostic significance of breast cancer index (BCI) in node-positive hormone receptor positive early breast cancer: NCIC CTG MA.14. Cancer Research. 2015
- Association between definitive surgery and times to administration of adjuvant chemotherapy and outcomes in early breast cancer: Analysis of adjuvant studies conducted by NCIC Clinical Trials Group (NCIC CTG). Cancer Research. 2015
- Circulating tumor cell (CTC) enumeration and HER2 assessment as predictors of breast cancer outcomes in the ALTTO (BIG 2-06, Alliance N063D) Trial. Cancer Research. 2015
- Introduction. American Journal of Clinical Oncology. 1-6. 2015
- Disease-Free Survival (Dfs) in the Lapatinib Alone Arm and Expanded Results of the Phase III Altto Trial (Big 2-06; Ncctg (Alliance) N063D) in the Adjuvant Treatment of Her2-Positive Early Breast Cancer (Ebc). Annals of Oncology. v1-v1. 2014
- First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L), or their combination (T plus L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).. Journal of Clinical Oncology. 2014
- A phase 1 multicenter clinical trial of alemtuzumab and CHOP chemotherapy for peripheral T-cell lymphomas.. Journal of Clinical Oncology. 8551-8551. 2014
- First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L), or their combination T plus L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).. Journal of Clinical Oncology. 2014
- Pharmacokinetic analysis of tamoxifen metabolites in premenopausal women with early breast cancer: A substudy of NCIC CTG MA.12 randomized clinical trial.. Journal of Clinical Oncology. 1524-1524. 2014
- Population-based evaluation of 21-gene assay in treatment decision making for early breast cancer in Ontario.. Journal of Clinical Oncology. 583-583. 2014
- Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.. Journal of Clinical Oncology. 11019-11019. 2014
- Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC).. Journal of Clinical Oncology. 504-504. 2014
- Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D).. Journal of Clinical Oncology. 647-647. 2014
- Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl).. Journal of Clinical Oncology. 542-542. 2014
- 1LBA Everolimus plus exemestane for hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2–) advanced breast cancer (BC): overall survival results from BOLERO-2. European Journal of Cancer. S1-S1. 2014
- Predicting anthracycline benefit: TOP2A and CEP17-not only but also. European Journal of Cancer. S164-S164. 2014
- Abstract P3-14-11: Microarray data analysis and long term outcomes of NCIC-CTG MA.22: Neoadjuvant epirubicin and docetaxel with pegfilgrastim support for locally advanced breast cancer. Cancer Research. 2013
- Abstract S4-07: Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials. Cancer Research. 2013
- Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.. Journal of Clinical Oncology. 151-151. 2013
- Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. Journal of Clinical Oncology. 155-155. 2013
- A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial. Journal of Clinical Oncology. 2013
- Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2.. Journal of Clinical Oncology. 2013
- Clinical management and resolution of stomatitis in BOLERO-2.. Journal of Clinical Oncology. 2013
- Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus anastrozole.. Journal of Clinical Oncology. 2013
- Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC). Journal of Clinical Oncology. 2013
- Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2.. Journal of Clinical Oncology. 2013
- Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. Journal of Clinical Oncology. 2013
- Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study-NCT00811369.. Journal of Clinical Oncology. 2013
- The first 10 years experience with genetic testing (GT) for BRCA1/2 mutations in a publicly funded program at a tertiary care teaching hospital in Ontario, Canada. Journal of Clinical Oncology. 2013
- Abstract P1-13-01: A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCIC CTG MA.21: Results of the final relapse free survival analysis.. Cancer Research. 2012
- Abstract P2-12-03: A pilot study evaluating the benefits and feasibility of an exercise program for breast cancer patients receiving adjuvant chemotherapy.. Cancer Research. 2012
- Abstract P2-13-02: Effect of aspirin (ASP) or celecoxib (CC) use on outcomes in postmenopausal breast cancer patients randomized to adjuvant exemestane or anastrozole: NCIC CTG MA.27. Cancer Research. 2012
- Abstract P6-08-04: The Impact of a Breast Cancer Diagnosis in Young Women on their Relationship with their Mothers. Cancer Research. 2012
- Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).. Journal of Clinical Oncology. 102-102. 2012
- Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. Journal of Clinical Oncology. 99-99. 2012
- Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2.. Journal of Clinical Oncology. 104-104. 2012
- EFFICACY AND SAFETY OF EVEROLIMUS IN POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST CANCER (BOLERO-2): EFFECT OF VISCERAL METASTASES AND PRIOR ENDOCRINE THERAPY. Annals of Oncology. 118-118. 2012
- SAFETY OF EVEROLIMUS FOR WOMEN OVER 65 YEARS OF AGE WITH ADVANCED BREAST CANCER: 18-MO FOLLOW-UP OF BOLERO-2. Annals of Oncology. 126-127. 2012
- Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919.. Journal of Clinical Oncology. LBA671-LBA671. 2012
- Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial.. Journal of Clinical Oncology. 2012
- Assessment of the prognostic and predictive utility of the breast cancer index (BCI): An NCIC CTG MA.14 study.. Journal of Clinical Oncology. 2012
- BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer.. Journal of Clinical Oncology. 2012
- BOLERO-2: Health-related quality-of-life in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane. Journal of Clinical Oncology. 2012
- Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets).. Journal of Clinical Oncology. 2012
- Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. Journal of Clinical Oncology. 2012
- Impact of concurrent (CON) and sequential (SEQ) radiotherapy (RT) with adjuvant aromatase inhibitors (AI) in early-stage breast cancer (EBC): NCIC CTG MA.27.. Journal of Clinical Oncology. 2012
- Lapatinib in HER2+early breast cancer: Quality of life analysis. Journal of Clinical Oncology. 2012
- Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study.. Journal of Clinical Oncology. 2012
- Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29. Journal of Clinical Oncology. 2012
- Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2.. Journal of Clinical Oncology. 2012
- Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. Journal of Clinical Oncology. 2012
- Everolimus (EVE) for Postmenopausal Women with Advanced Breast Cancer (ABC) Refractory to Letrozole or Anastrozole: Long-term Efficacy and Safety Results of the BOLERO-2 Trial. European Journal of Cancer. S116-S116. 2012
- Everolimus Added to Exemestane Reduced Bone Markers and Disease Progression in Bone in Postmenopausal Women with Advanced Breast Cancer: Updated Results From the BOLERO-2 Trial. European Journal of Cancer. S2-S2. 2012
- Everolimus Added to Exemestane Reduced Bone Markers in Postmenopausal Women with Advanced Breast Cancer (ABC): the BOLERO-2 Trial. European Journal of Cancer. S43-S43. 2012
- How Should We Assess Tumour Size (T Stage) in Patients with Multicentric/Multifocal Breast Cancer? Results from the NCIC CTG MA.5 Randomized Trial of CEF vs. CMF in Pre-Menopausal Women with Node Positive Breast Cancer.. Cancer Research. 2011
- P1-06-07: TIMP-1 in Combination with HER2 and TOP2A for Prediction of Benefit from Adjuvant Anthracyclines in High Risk Breast Cancer Patients.. Cancer Research. 2011
- P1-06-08: Effect of Treatment Emergent Symptoms on Relapse Free Survival: NCIC CTG MA.12 a Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women in Early Breast Cancer.. Cancer Research. 2011
- P2-12-27: Simply Adding Together the Diameters of Tumor Foci in Patients with Multicentric or Multifocal Disease Does Not Add Any Additional Prognostic Information: An Analysis from NCIC CTG MA.12 Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women with Early Breast Cancer.. Cancer Research. 2011
- P2-12-28: Studies of a Malignancy-Associated Protein, Osteopontin, in NCIC CTG MA.14, a Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR in Adjuvant Treatment of Women with Early Breast Cancer.. Cancer Research. 2011
- P4-01-04: Effects of CYP2D6 Phenotype and Drug Adherence on Tamoxifen Metabolite Levels.. Cancer Research. 2011
- P4-12-05: Impact of the Lifestyle Intervention Study in Adjuvant Treatment of Early Breast Cancer (LISA) Weight Loss Intervention upon Physical Activity.. Cancer Research. 2011
- P5-14-01: Differences in Efficacy by Assessment Method: NCIC CTG Adjuvant Breast Cancer Trials MA.5, MA.12, MA.14, MA.21, MA.27 Meta-Analysis.. Cancer Research. 2011
- P5-17-06: Pilot Study of a Questionnaire To Assess Impact of a Breast Cancer Diagnosis in Young Women on Their Relationship with Their Mothers.. Cancer Research. 2011
- S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial.. Cancer Research. 2011
- BOLERO-2: Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive ADVANCED breast cancer refractory to letrozole or anastrozole. Breast. S30-S30. 2011
- Prediction of late recurrences by breast cancer index in the NCIC CTG MA.17 cohort.. Journal of Clinical Oncology. 2-2. 2011
- The effect of trastuzumab on pCR in locally advanced HER2-positive breast cancer.. Journal of Clinical Oncology. 286-286. 2011
- NCIC-CTG MA. 20: An intergroup trial of regional nodal irradiation in early breast cancer. Journal of Clinical Oncology. 2011
- A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC) (NCIC Clinical Trials Group MA.32).. Journal of Clinical Oncology. TPS103-TPS103. 2011
- Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial.. Journal of Clinical Oncology. e11058-e11058. 2011
- Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer.. Journal of Clinical Oncology. 513-513. 2011
- Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.. Journal of Clinical Oncology. 577-577. 2011
- NCIC CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer.. Journal of Clinical Oncology. 2011
- Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919).. Journal of Clinical Oncology. TPS108-TPS108. 2011
- Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results.. Journal of Clinical Oncology. 512-512. 2011
- Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial.. Journal of Clinical Oncology. 525-525. 2011
- The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial.. Journal of Clinical Oncology. 1032-1032. 2011
- Abstract P2-09-16: Effect of Continuous Statistically Standardized qPCR and IHC ER and PR on Disease-Free Survival in NCIC CTG MA.12. Cancer Research. 2010
- Abstract P2-16-06: Final Overall Survival Results, Including Analysis of Patients with Triple-Negative Disease and Aged ≥70 Years, from the ATHENA Study Evaluating First-Line Bevacizumab-Containing Therapy for Locally Recurrent/Metastatic Breast Cancer. Cancer Research. 2010
- Abstract P3-10-26: Quantitative Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC CTG MA.17 Cohort. Cancer Research. 2010
- Abstract P4-09-09: Serum SDF-1: Biomarker of Bone Relapse in the NCIC MA.14 Adjuvant Breast Cancer Trial. Cancer Research. 2010
- Abstract P6-12-01: A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF) Therapy — Bevacizumab. Cancer Research. 2010
- Abstract S1-1: Final Analysis of NCIC CTG MA.27: A Randomized Phase III Trial of Exemestane Versus Anastrozole in Postmenopausal Women with Hormone Receptor Positive Primary Breast Cancer. Cancer Research. 2010
- A phase I/II study of increasing doses of epirubicin (E) and docetaxel (D) plus pegfilgrastim (Pegf) for locally advanced (LABC) or inflammatory breast cancer (IBC): NCIC CTG MA.22.. Journal of Clinical Oncology. 629-629. 2010
- A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors.. Journal of Clinical Oncology. 9023-9023. 2010
- Final results of a meta-analysis testing HER2 and topoisomerase II alpha genes as predictors of incremental benefit from anthracyclines in breast cancer.. Journal of Clinical Oncology. 2010
- Obesity, patient characteristics, and TIMP-1: Effects on non-bone RFS in NCIC CTG MA.14.. Journal of Clinical Oncology. 562-562. 2010
- Patterns of antidepressant use among women initiating tamoxifen therapy for the treatment of breast cancer in Ontario, Canada.. Journal of Clinical Oncology. 1592-1592. 2010
- Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methothrexate, and daily prednisone (DalCMP) as therapy for metastatic breast cancer (MBC).. Journal of Clinical Oncology. 1152-1152. 2010
- Prospective change in 25-OH vitamin D levels over long-term follow-up and health outcomes in breast cancer survivors.. Journal of Clinical Oncology. 6111-6111. 2010
- Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early-stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial.. Journal of Clinical Oncology. 542-542. 2010
- Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.. Journal of Clinical Oncology. 551-551. 2010
- 213 Duplication of chromosome 17 CEP predicts for anthracycline benefit: evidence from an international meta-analysis of 4 adjuvant breast cancer trials for the HER2/TOP2A meta-analysis study group. European Journal of Cancer, Supplement. 121-121. 2010
- 415 Comparison of two Phase II trials evaluating three dosing regimens of fulvestrant in Japanese vs non-Japanese postmenopausal women with advanced breast cancer (FINDER1 and FINDER2). European Journal of Cancer, Supplement. 178-178. 2010
- A Phase II Study (FINDER 2) Comparing Three Dosing Regimens of Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer. Cancer Research. 738S-738S. 2009
- Duplication of Chromosome 17 CEP Predicts for Anthracycline Benefit: A Meta-Analysis of 4 Trials. Cancer Research. 716S-716S. 2009
- Examination of TIMP-1 Levels and Relapse-Free Survival for Patients in NCIC CTG MA.14 Who Received Adjuvant Tamoxifen+/- Octreotide LAR.. Cancer Research. 653S-653S. 2009
- First-Line Bevacizumab (Bev) Combination Therapy in Triple-Negative (TN) Locally Recurrent/Metastatic Breast Cancer (LR/MBC): Subpopulation Analysis of Study MO19391 in > 2000 Patients (Pts).. Cancer Research. 854S-854S. 2009
- Outcomes of Women Who Were Premenopausal at Diagnosis of Early Stage Breast Cancer in the NCIC CTG MA17 Trial.. Cancer Research. 487S-487S. 2009
- Prognostic and Predictive Impact of Intrinsic Biological Classification by Immunohistochemistry (IHC) and QPCR for Adjuvant Tamoxifen in Pre-Menopausal Breast Cancer: Results from the NCIC CTG MA.12 Trial. Cancer Research. 725S-725S. 2009
- Risk of Death Due to Breast Cancer in Women Treated with Selective Serotonin Reuptake Inhibitor Antidepressants and Tamoxifen. Cancer Research. 608S-608S. 2009
- Treatment-Emergent Symptoms and the Risk of Breast Cancer Recurrence in the NCIC CTG MA.27 Adjuvant Aromatase Inhibitor Trial. Cancer Research. 488S-488S. 2009
- DELTA: A Randomized Trial of Decongestive Lymphatic Therapy for Women with Lymphedema following Treatment for Breast Cancer. International Journal of Radiation Oncology Biology Physics. S53-S53. 2009
- Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163. Journal of Clinical Oncology. 4536-4541. 2009
- 5017 Multinational study (n = 2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391. European Journal of Cancer, Supplement. 265-266. 2009
- 5160 Long-term prognostic effects of fasting insulin in early stage breast cancer (BC) patients. European Journal of Cancer, Supplement. 308-308. 2009
- A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium. Journal of Clinical Oncology. 2009
- Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF. Journal of Clinical Oncology. 2009
- Cost-effectiveness analysis of oncotype DX-guided treatment in early breast cancer. Journal of Clinical Oncology. 2009
- Effect of adjuvant chemotherapy on bone resorption marker beta C-telopeptide (B-CTX) in postmenopausal women. Journal of Clinical Oncology. 2009
- Safety and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): Analysis of MO19391 according to CT. Journal of Clinical Oncology. 2009
- Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. Journal of Clinical Oncology. 2009
- Tolerability and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) in elderly patients with advanced breast cancer (aBC): Subpopulation analysis of the MO19391 study. Journal of Clinical Oncology. 2009
- 0068 Elevated bone resorption predicts shorter recurrence-free survival (RFS) for bone metastasis in breast cancer (BC). Breast. S35-S35. 2009
- A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breastcancer patients treated with CMF or anthracycline-based adjuvant therapy. Cancer Research. 99S-99S. 2009
- Chromosome 17 polysomy: a unifying hypothesis underlying benefit from adjuvant anthracyclines?. Cancer Research. 364S-364S. 2009
- Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC). Cancer Research. 286S-286S. 2009
- Reductions in tumor RNA integrity associated with clinical response to epirubicin/docetaxel chemotherapy in breast cancer patients. Cancer Research. 367S-367S. 2009
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100). Breast Cancer Research and Treatment. 585-585. 2008
- A prospective study evaluating 18F-Fluorodeoxyglucose (18FDG) positron emission tomography (PET) in the assessment of axillary nodal spread in women undergoing sentinel lymph node biopsy (SLNB) for breast cancer. Journal of Clinical Oncology. 533-533. 2008
- Frequency of vitamin D (Vit D) deficiency at breast cancer (BC) diagnosis and association with risk of distant recurrence and death in a prospective cohort study of T1-3, N0-1, M0 B. Journal of Clinical Oncology. 2008
- MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC). Journal of Clinical Oncology. 1140-1140. 2008
- NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam plus octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer. Journal of Clinical Oncology. 2008
- Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial. Journal of Clinical Oncology. 550-550. 2008
- Use of elevated bone turnover to predict bone metastasis. Journal of Clinical Oncology. 591-591. 2008
- Combining endocrine agents with chemotherapy: Which patients and what sequence?. Cancer. 718-722. 2008
- Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer. Cancer. 260-267. 2008
- How compliant are patients with oral hormonal therapies? Data from a randomized, placebo controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (NCIC CTG MA.12). Breast Cancer Research and Treatment. S144-S144. 2007
- 2123 POSTER MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC). European Journal of Cancer, Supplement. 221-221. 2007
- Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. Journal of Clinical Oncology. 2006-2011. 2007
- A randomized trial of CEF versus dose dense EC followed by paclitaxel versus AC followed by paclitaxel in women with node positive or high risk node negative breast cancer, NCICCTG MA. 21: Results of an interim analysis. Breast Cancer Research and Treatment. 117-117. 2007
- P46 Patterns of recurrence and prognosis in women with basal-like breast cancer. Breast. S25-S25. 2007
- S35 Adjuvant treatment of the very young woman. Breast. S10-S10. 2007
- Adjuvant therapy of the very young woman. Breast. 136-146. 2007
- A phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. Breast Cancer Research and Treatment. 342-342. 2006
- A randomized controlled trial (RCT) of long-term follow-up for early stage breast cancer comparing family physician to specialist care: A report of secondary outcomes.. Journal of Clinical Oncology. 301S-301S. 2006
- Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCICCTG MA.14 adjuvant breast cancer trial.. Journal of Clinical Oncology. 9S-9S. 2006
- Left ventricular function following adjuvant chemotherapy for breast cancer: The NCICCTG MA5 experience.. Journal of Clinical Oncology. 8S-8S. 2006
- Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5).. Journal of Clinical Oncology. 11S-11S. 2006
- Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast Cancer. Clinical Cancer Research. 1031s-1036s. 2006
- Anastrozole as an Adjuvant Endocrine Treatment for Postmenopausal Patients with Breast Cancer: Emerging Data. Clinical Cancer Research. 1037s-1048s. 2006
- ErbB Receptor Signaling and Therapeutic Resistance to Aromatase Inhibitors. Clinical Cancer Research. 1008s-1012s. 2006
- Managing patients on endocrine therapy: Focus on quality-of-life issues. Clinical Cancer Research. 1056S-1060S. 2006
- Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: Conference Summary Statement. Clinical Cancer Research. 997s-1000s. 2006
- Progesterone Receptor Loss Correlates with Human Epidermal Growth Factor Receptor 2 Overexpression in Estrogen Receptor–Positive Breast Cancer. Clinical Cancer Research. 1013s-1018s. 2006
- Canadian clinical practice patterns survey of adjuvant therapies for breast cancer.. Breast Cancer Research and Treatment. S116-S116. 2006
- Metformin lowers fasting insulin levels in nondiabetic hyperinsulinemic early stage breast cancer (BC) patients - results of a phase II study.. Breast Cancer Research and Treatment. S109-S109. 2006
- The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age.. Breast Cancer Research and Treatment. S23-S23. 2006
- Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5).. Breast Cancer Research and Treatment. S18-S18. 2006
- A study of surveillance mammography (SM) of the contralateral breast (CLB) following total mastectomy (TM) for breast cancer (BC).. Journal of Clinical Oncology. 540S-540S. 2005
- ABREAST: A new global registry of adjuvant strategies in patients with early stage breast cancer.. Journal of Clinical Oncology. 22S-22S. 2005
- Determinants of preferences for starting extended adjuvant letrozole (L) in postmenopausal women following five years of tamoxifen.. Journal of Clinical Oncology. 39S-39S. 2005
- Phase I-II study of DaICM-P [daily dalteparin (Dal), cyclophosphamide (C) and prednisone (P) and bi-weekly methotrexate (M)] as therapy for metastatic breast cancer (MBC).. Journal of Clinical Oncology. 52S-52S. 2005
- Subgroup analysis of a phase III trial of doxorubicin vs doxorubicin plus tesmilifene in advanced breast cancer (ABC): Tesmilifene survival benefit focused on patients with more aggressive disease.. Journal of Clinical Oncology. 67S-67S. 2005
- The prognostic effect of lipids on early-stage breast cancer (BC) outcome.. Journal of Clinical Oncology. 55S-55S. 2005
- Phenyl N-Tert-Butylnitrone (PBN) Protects Syngeneic Marrow Transplant Recipients from the Lethal Cytokine Syndrome Occurring after Agonistic CD40 Antibody Administration.. Blood. 2128-2128. 2004
- Why Cancer Patients Enter Randomized Clinical Trials: Exploring the Factors That Influence Their Decision. Journal of Clinical Oncology. 4312-4318. 2004
- Arm lymphedema in breast cancer patients: Is it always related to treatment. International Journal of Radiation Oncology Biology Physics. S402-S402. 2004
- Clinical screening for lymphedema in breast cancer patients: Validation of Canadian guidelines.. Radiotherapy and Oncology. S42-S42. 2004
- Lymphedema in breast cancer patients screened during the first year of a randomized trial: Is treatment always the cause?. Radiotherapy and Oncology. S42-S42. 2004
- Virtual wedge and intensity modulated radiotherapy reduce the magnitude of scattered radiation during adjuvant breast radiation.. Radiotherapy and Oncology. S56-S57. 2004
- An audiotape intervention to enhance informed consent to clinical trials in breast oncology. Psycho-Oncology. S32-S33. 2004
- A randomized controlled trial (RCT) of routine follow-up for early stage breast cancer: A comparison of primary care versus specialist care.. Journal of Clinical Oncology. 43S-43S. 2004
- Association of young age and chemotherapy with psychosocial distress and health-related quality of life (HRQOL) during the first year after breast cancer (BC).. Journal of Clinical Oncology. 732S-732S. 2004
- Patterns of trastuzumab (T) use in three Canadian provinces.. Journal of Clinical Oncology. 35S-35S. 2004
- Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. Journal of Clinical Oncology. 269-276. 2004
- Effect of letrozole versus placebo on bone mineral density in women completing >= 5 years (yrs) of adjuvant tamoxifen: ncic ctg ma.17b. Breast Cancer Research and Treatment. S36-S36. 2004
- Estimate of prognosis for node negative breast cancer patients is affected by survival analysis model.. Breast Cancer Research and Treatment. S192-S192. 2004
- Virtual wedge and intensity modulated radiotherapy reduce the magnitude of scattered radiation during adjuvant breast radiation. International Journal of Radiation Oncology Biology Physics. S622-S623. 2004
- Virtual wedge and intensity modulated radiotherapy reduce the magnitude of scattered radiation during adjuvant breast radiation.. Breast Cancer Research and Treatment. S165-S165. 2004
- The best use of adjuvant endocrine treatments. Breast. 497-508. 2003
- Endocrine therapy of advanced disease: Analysis and implications of the existing data. Clinical Cancer Research. 460S-467S. 2003
- A randomized trial comparing CEF to CME in premenopausal women with node positive breast cancer: update of NCICCTG MA.5.. Breast Cancer Research and Treatment. S33-S33. 2002
- Health related quality of life (HRQOL) and psychosocial status at diagnosis are not associated with disease-free or overall survival (DFS or OS) in T1-3, N0-1, M0 breast cancer (BC).. Breast Cancer Research and Treatment. S43-S43. 2002
- How recruiting patients to clinical trials affects the doctor/patient relationship. European Journal of Cancer. S92-S92. 2002
- The NCIC CTG MA.14 experience with the gallbladder toxicity of octreotide pamoate (oncolar) in a postmenopausal patient population undergoing adjuvant treatment for stage 1-3 breast cancer. European Journal of Cancer. S93-S93. 2002
- 4F, an Apo A-1 mimetic, confers cardioprotection by inhibiting uncoupled NOS activity. Free Radical Biology and Medicine. S323-S324. 2002
- Hypoxia-induced acute lung injury in murine models of sickle cell disease. Free Radical Biology and Medicine. S366-S366. 2002
- Increased association of HSP90 with NOS3 in hearts of Brown Norway rats increases resistance to myocardial ischemia. Free Radical Biology and Medicine. S371-S371. 2002
- The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients. Clinical Cancer Research. 4356S-4359S. 2001
- Optimal endocrine therapy. Breast. 114-122. 2001
- Future direction panel discussion. Clinical Cancer Research. 2001
- Risk of acute leukemia following adjuvant epirubicin-based adjuvant chemotherapy for breast cancer.. Breast Cancer Research and Treatment. 247-247. 2001
- The BEST study - A Canadian multicenter randomized trial of group psychosocial support in metastatic breast cancer. Early results.. Psycho-Oncology. S43-S43. 2000
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement. Proceedings of a conference held at Boar's Head Inn, Charlottesville, Virginia, September 21-23, 1997.. Oncology. 859-861. 1999
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 5: Selective estrogen receptor modulators and hormone replacement therapy. Proceedings of a conference. Charlottesville, Virginia, USA. September 21-23, 1997.. Oncology. 721-724. 1999
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 3: Prevention of osteoporosis and CV effects of estrogens and antiestrogens.. Oncology. 397-399. 1999
- 21st Annual San Antonio Breast Cancer Symposium, December 12-15, 1998. Current Oncology. 14-19. 1999
- 22nd Annual San Antonio Breast Cancer Symposium, December 8-11, 1999. Current Oncology. 205-210. 1999
- 35th Annual Meeting of the American Society of Clinical Oncology: What's new in breast cancer. Current Oncology. 69-73. 1999
- Doxorubicin-induced apoptosis is reversed by nitrone spin traps & ebselen. Free Radical Biology and Medicine. S117-S117. 1999
- S28 GNRH analogues and ovarian ablation: How to integrate in the adjuvant strategy. European Journal of Cancer. S7-S7. 1998
- S35 CEF versus CMF in premenopausal women — Recent update. European Journal of Cancer. S9-S9. 1998
- 20th annual San Antonio Breast Cancer Symposium, December 3-6, 1997. Current Oncology. 23-27. 1998
- International St. Gallen conference: Adjuvant therapy of primary breast cancer, February 25-28, 1998. Current Oncology. 80-84. 1998
- Liver metastases: Can our understanding of their biology and prognostic value contribute to a strategy for optimum therapeutic management?. European Journal of Cancer. S11-S14. 1997
- Development of a weight management program in women with newly diagnosed locoregional breast cancer. PSYCHOSOMATIC OBSTETRICS AND GYNAECOLOGY. 491-496. 1995
- The BEST Study: A multicentre randomized trial of group psychosocial support in metastatic breast cancer. PSYCHOSOMATIC OBSTETRICS AND GYNAECOLOGY. 511-516. 1995
- Clinical cooperative trials of the national cancer institute of Canada clinical trials group breast cancer site group. Cancer. 1150-1155. 1994
- CALDESMON ISOFORMS IN SMOOTH-MUSCLE CELLS IN INTIMAL PROLIFERATION AND ATHEROSCLEROSIS. Biophysical Journal. A197-A197. 1994
- DIFFERENTIAL MESSENGER-RNA SPLICING CONTROLS CALDESMON ISOFORM EXPRESSION. Biophysical Journal. A198-A198. 1994
- EXERCISE-INDUCED SHEAR STRESS UPREGULATES ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE GENE EXPRESSION. BIOLOGY OF NITRIC OXIDE, PT 3. 1-3. 1994
- A DOUBLE-BLIND RANDOMIZED TRIAL OF MINI-DOSE WARFARIN FOR THE PREVENTION OF THROMBOEMBOLISM (TE) IN PATIENTS WITH STAGE-IV BREAST-CANCER. Thrombosis and Haemostasis. 981-981. 1993
- A MULTI-CENTERED RANDOMIZED TRIAL OF GROUP PSYCHOSOCIAL SUPPORT IN METASTATIC BREAST-CANCER - PILOT RESULTS. Quality of Life Research. 54-54. 1993
- Summary. American Journal of Clinical Oncology. 62-63. 1991
- COMPARISON OF ANTIESTROGEN AND PROGESTOGEN THERAPY FOR INITIAL TREATMENT AND CONSEQUENCES OF THEIR COMBINATION FOR 2ND-LINE TREATMENT OF RECURRENT BREAST-CANCER. Seminars in Oncology. 52-62. 1990
- The control of calcium-regulated thin filaments from vascular smooth muscle by calmodulin and other calcium-binding proteins. Biochemical Society Transactions. 355-356. 1988
- ENDOCRINE ACTIONS OF TAMOXIFEN THERAPY IN PREMENOPAUSAL PATIENTS WITH BREAST-CANCER. Breast Cancer Research and Treatment. 110-110. 1987
- PHASE-I-II STUDY OF FLUTAMIDE IN METASTATIC BREAST-CANCER. Breast Cancer Research and Treatment. 90-90. 1986
- PROGNOSTIC FACTORS (PF) IN POSTMENOPAUSAL WOMEN WITH AXILLARY NODE POSITIVE BREAST-CANCER (AN+). Breast Cancer Research and Treatment. 164-164. 1985
- PROGNOSTIC FACTORS (PF) IN POSTMENOPAUSAL WOMEN WITH AXILLARY NODE POSITIVE BREAST-CANCER (AN+). Clinical and Investigative Medicine. A164-A164. 1985
- A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF ADJUVANT TAMOXIFEN IN POSTMENOPAUSAL WOMEN WITH AXILLARY NODE-POSITIVE BREAST-CANCER. American Journal of Clinical Oncology. 118-118. 1984
- COMBINED MODALITY INDUCTION THERAPY WITHOUT MAINTENANCE CHEMOTHERAPY FOR SMALL CELL-CARCINOMA OF LUNG (SCCL). Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 494-494. 1981
- THE FREQUENCY OF MALIGNANCY IN PATIENTS WITH POLYMYOSITIS-DERMATOMYOSITIS (PM-DM) - A 15-YEAR CONTROLLED FOLLOW-UP-STUDY. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 334-334. 1981
- THE INFLUENCE OF TAMOXIFEN ON MENSTRUATION AND SERUM HORMONE LEVELS IN PREMENOPAUSAL PATIENTS WITH METASTATIC BREAST-CANCER. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 145-145. 1981
- THE ROLE OF TAMOXIFEN IN PREMENOPAUSAL WOMEN WITH METASTATIC CARCINOMA OF THE BREAST - AN UPDATE. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 436-436. 1981
- CYCLOPHOSPHAMIDE, ADRIAMYCIN, AND CIS-PLATINUM IN THE TREATMENT OF NON-SMALL CELL LUNG-CANCER (NSCLC). Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 447-447. 1980
- TAMOXIFEN RESPONSE - A USEFUL GUIDE TO SUBSEQUENT TREATMENT IN PREMENOPAUSAL PATIENTS WITH METASTATIC BREAST-CANCER. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 407-407. 1980
- GLOMERULONEPHRITIS OF POLYMYOSITIS. Arthritis and Rheumatism. 554-554. 1978
- LIVER AND BONE SCANS - ARE THEY USEFUL IN STAGING LUNG-CANCER. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 89-89. 1978
- PREVALANCE OF SJOGREN SYNDROME IN NON-HODGKIN LYMPHOMA. Arthritis and Rheumatism. 585-585. 1978
- PREVALENCE OF SJOGRENS SYNDROME IN NON-HODGKINS LYMPHOMA. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 418-418. 1978
- TREATMENT OF METASTATIC MALIGNANT-MELANOMA WITH IMIDAZOLE CARBOXAMIDE (DTIC), CYCLOPHOSPHAMIDE AND VINCRISTINE, USING A SIMPLIFIED DTIC DOSAGE SCHEDULE. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 199-199. 1977
- DTIC THERAPY IN METASTATIC MALIGNANT-MELANOMA - SIMPLIFIED DOSAGE SCHEDULE. Proceedings / Annual Meeting of the American Association for Cancer Research [and] Annual Meeting of the American Society of Clinical Oncology. American Association for Cancer Research. Meeting. 215-215. 1976
-
journal articles
- Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy—a sub-analysis of the ALTTO study. British Journal of Cancer. 127:1799-1807. 2022
- Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies. Nature Communications. 13:3607. 2022
- Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials. Clinical Cancer Research. 27:6570-6579. 2021
- The association between endocrine therapy use and osteoporotic fracture among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. Breast. 60:295-301. 2021
- Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience. Breast Cancer Research and Treatment. 184:733-741. 2020
- The association between endocrine therapy use and dementia among post-menopausal women treated for early-stage breast cancer in Ontario, Canada. Journal of Geriatric Oncology. 11:1132-1137. 2020
- The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer.. npj Breast Cancer. 6:6. 2020
- Incidence of Brain Metastases in Nonmetastatic and Metastatic Breast Cancer: Is There a Role for Screening?. Clinical Breast Cancer. 20:e54-e64. 2020
- Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. npj Breast Cancer. 6:22. 2020
- The LISA randomized trial of a weight loss intervention in postmenopausal breast cancer. npj Breast Cancer. 6:6. 2020
- A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer. Breast Cancer. 26:703-711. 2019
- Identifying research priorities in the treatment of patients with early breast cancer: from the patient perspective. Breast. 48:S21-S22. 2019
- Breast Cancer Screening: Beyond Mortality. Journal of Breast Imaging. 1:161-165. 2019
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. New England Journal of Medicine. 380:2395-2405. 2019
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. The Lancet. 393:1440-1452. 2019
- Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. Journal of the National Cancer Institute. 111:86-94. 2019
- Bone-Targeted Therapy in Early Breast Cancer.. Oncology. 32:562-569. 2018
- Thyroid hormone receptor beta-1 expression in early breast cancer: a validation study. Breast Cancer Research and Treatment. 171:709-717. 2018
- Effects of Celecoxib and Low-dose Aspirin on Outcomes in Adjuvant Aromatase Inhibitor–Treated Patients: CCTG MA.27. Journal of the National Cancer Institute. 110:1003-1008. 2018
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine. 379:111-121. 2018
- Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab. Breast Cancer Research and Treatment. 170:169-177. 2018
- Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada. Oncologist. 23:768-775. 2018
- Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases. Scientific Reports. 8:9013. 2018
- An update on treatment for post-menopausal metastatic breast cancer in elderly patients. Expert Opinion on Pharmacotherapy. 19:597-609. 2018
- Cognitive sequelae of endocrine therapy in women treated for breast cancer: a meta-analysis. Breast Cancer Research and Treatment. 168:299-310. 2018
- Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis. European Journal of Cancer. 91:38-46. 2018
- Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. Journal of Clinical Oncology. 36:563-571. 2018
- Vitamin D Levels, Vitamin D Receptor Polymorphisms, and Inflammatory Cytokines in Aromatase Inhibitor-Induced Arthralgias: An Analysis of CCTG MA.27. Clinical Breast Cancer. 18:78-87. 2018
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. The Lancet Oncology. 19:27-39. 2018
- Reply to ‘The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology’ by Kirova et al.. Annals of Oncology. 29:281-282. 2018
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. New England Journal of Medicine. 377:1836-1846. 2017
- Extended adjuvant therapy: the role of subset analyses. The Lancet Oncology. 18:1431-1433. 2017
- Palbociclib in hormone receptor positive advanced breast cancer: A cost-utility analysis. European Journal of Cancer. 85:146-154. 2017
- Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities. Scientific Reports. 7:10352. 2017
- De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Annals of Oncology. 28:1700-1712. 2017
- Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. Breast Cancer Research and Treatment. 164:371-378. 2017
- Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Annals of Oncology. 28:1560-1568. 2017
- Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor–positive breast cancer: NCIC CTG MA.27. Cancer. 123:2444-2451. 2017
- Correction: Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach. Oncotarget. 8:35481-35481. 2017
- Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. Journal of Clinical Oncology. 35:1641-1649. 2017
- A priori Prediction of Neoadjuvant Chemotherapy Response and Survival in Breast Cancer Patients using Quantitative Ultrasound. Scientific Reports. 7:45733. 2017
- Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. Journal of Clinical Oncology. 35:1041-1048. 2017
- Can we efficiently and safely combine a pan-class I phosphatidylinositol-3-kinase inhibitor with paclitaxel in metastatic breast cancer?. Translational Cancer Research. 6:S259-S264. 2017
- Does Adjuvant Radiation Therapy Benefit Women with Small Mammography-Detected Breast Cancers?. Current Oncology. 24:28-32. 2017
- Domain Mapping of Heat Shock Protein 70 Reveals That Glutamic Acid 446 and Arginine 447 Are Critical for Regulating Superoxide Dismutase 2 Function. Journal of Biological Chemistry. 292:2369-2378. 2017
- Enhancing Endocrine Therapy Combination Strategies for the Treatment of Postmenopausal HR+/HER2– Advanced Breast Cancer. Oncologist. 22:12-24. 2017
- Plasma vascular endothelial growth factor as a predictive biomarker: Door closed?. European Journal of Cancer. 70:143-145. 2017
- Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. Breast Cancer Research. 18:1. 2016
- Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Research. 76:7012-7023. 2016
- Do aromatase inhibitors increase cardiovascular risk? Piecing together the evidence. European Journal of Cancer. 68:176-178. 2016
- The 21-gene recurrence score assay in node-negative early breast cancer: Prognostic, predictive or presumptuous?. European Journal of Cancer. 68:173-175. 2016
- An update on adjuvant systemic therapy for elderly patients with early breast cancer. Expert Opinion on Pharmacotherapy. 17:1881-1888. 2016
- Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies. Breast Cancer Research and Treatment. 158:407-420. 2016
- Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. Journal of the National Cancer Institute. 108:djw037-djw037. 2016
- Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. New England Journal of Medicine. 375:209-219. 2016
- Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach. Oncotarget. 7:45094-45111. 2016
- New onset vasomotor symptoms but not musculoskeletal symptoms associate with clinical outcomes on extended adjuvant letrozole – Analyses from NCIC CTG MA.17. Breast. 27:99-104. 2016
- Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. Breast Cancer Research and Treatment. 157:101-108. 2016
- Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. Journal of Clinical Oncology. 34:1034-1042. 2016
- Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. Breast Cancer Research and Treatment. 156:343-349. 2016
- Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. Journal of Clinical Oncology. 34:1065-1071. 2016
- Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies. Journal of Clinical Oncology. 34:895-897. 2016
- Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. European Journal of Cancer. 56:85-92. 2016
- The effect of melatonin on sleep and quality of life in patients with advanced breast cancer. Supportive Care in Cancer. 24:1097-1105. 2016
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2. Journal of Clinical Oncology. 34:419-426. 2016
- A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22. SpringerPlus. 4:631. 2015
- Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy. Breast Cancer Research. 17:56. 2015
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine. 373:2005-2014. 2015
- A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials. Oncotarget. 6:31693-31701. 2015
- Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. The Lancet. 386:1353-1361. 2015
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. The Lancet. 386:1341-1352. 2015
- Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. Breast Cancer Research and Treatment. 153:353-360. 2015
- Regional Nodal Irradiation in Early-Stage Breast Cancer. New England Journal of Medicine. 373:307-316. 2015
- Hepatitis B virus screening before adjuvant chemotherapy in patients with early-stage breast cancer: a cost-effectiveness analysis. Breast Cancer Research and Treatment. 151:639-652. 2015
- Predicting Anthracycline Benefit: TOP2A and CEP17—Not Only but Also. Journal of Clinical Oncology. 33:1680-1687. 2015
- Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. Journal of Clinical Oncology. 33:1574-1583. 2015
- 18F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer. British Journal of Cancer. 112:1737-1743. 2015
- Defining Breast Cancer Intrinsic Subtypes by Quantitative Receptor Expression. Oncologist. 20:474-482. 2015
- Erratum to: Platinum-based chemotherapy in triple-negative advanced breast cancer. Breast Cancer Research and Treatment. 150:697-697. 2015
- Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. European Journal of Cancer. 51:685-696. 2015
- Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Research and Treatment. 150:605-611. 2015
- Effect of Metformin vs Placebo on and Metabolic Factors in NCIC CTG MA.32. Journal of the National Cancer Institute. 107:djv006-djv006. 2015
- In Vitro Screening for Drug Repositioning. SLAS Discovery. 20:167-179. 2015
- Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial. Journal of Clinical Oncology. 33:265-271. 2015
- Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. Breast Cancer Research and Treatment. 149:439-448. 2015
- The role of bisphosphonates in early- and advanced-stage breast cancer: have we finally optimized care?. Oncology. 29:23-37. 2015
- Thyroid hormone receptor α in breast cancer: prognostic and therapeutic implications. Breast Cancer Research and Treatment. 149:293-301. 2015
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Annals of Oncology. 25:2357-2362. 2014
- A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial. Breast. 23:656-662. 2014
- Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Advances in Therapy. 31:1008-1009. 2014
- Platinum-based chemotherapy in triple-negative advanced breast cancer. Breast Cancer Research and Treatment. 146:567-572. 2014
- Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial. Journal of Clinical Oncology. 32:2231-2239. 2014
- Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study. Breast Cancer Research and Treatment. 146:153-162. 2014
- Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture. Oncotarget. 5:3497-3511. 2014
- Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Annals of Oncology. 25:992-998. 2014
- Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Annals of Oncology. 25:763-773. 2014
- Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. The Lancet Oncology. 15:474-482. 2014
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Annals of Oncology. 25:808-815. 2014
- Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Research. 16:R8. 2014
- Overdiagnosing Overdiagnosis. Oncologist. 19:103-106. 2014
- The impact of a breast cancer diagnosis in young women on their relationship with their mothers. Breast. 23:50-55. 2014
- Competing risks of death in younger and older postmenopausal breast cancer patients. World Journal of Clinical Oncology. 5:1088-1088. 2014
- Validated or Not Validated? That Is the Question. Journal of the National Cancer Institute. 106:djt360-djt360. 2014
- Symptoms and Cancer Outcome in Adjuvant Endocrine Therapy for Breast Cancer: Why Are They Associated?. Journal of Clinical Oncology. 31:4476-4476. 2013
- Adjuvant endocrine therapy for breast cancer: longer therapy and the need for personalized treatment--should we treat beyond the data?. Oncology. 27:1230-1231. 2013
- Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2. Clinical Breast Cancer. 13:421-432.e8. 2013
- Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trials. Breast Cancer Research and Treatment. 142:143-151. 2013
- Health-related quality of life and disease symptoms in postmenopausal women with HR+, HER2−advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Current Medical Research and Opinion. 29:1463-1473. 2013
- Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer. Journal of Clinical Oncology. 31:3758-3763. 2013
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis. Advances in Therapy. 30:870-884. 2013
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology. 24:2206-2223. 2013
- Effect of continuous statistically standardized measures of estrogen and progesterone receptors on disease-free survival in NCIC CTG MA.12 Trial and BC Cohort. Breast Cancer Research. 15:R71. 2013
- Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study. European Journal of Cancer. 49:2621-2632. 2013
- Endocrine therapy: is the first generation of targeted drugs the last?. Journal of Internal Medicine. 274:144-152. 2013
- Expression of both Estrogen Receptor-beta 1 (ER-β1) and its co-regulator Steroid Receptor RNA Activator Protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with Estrogen Receptor-alpha (ER-α)-Negative Early Breast Cancer (EBC). Annals of Oncology. 24:1986-1993. 2013
- Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker. Journal of the National Cancer Institute. 105:1036-1042. 2013
- Health‐related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO‐2 trial. Cancer. 119:1908-1915. 2013
- Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2. Journal of the National Cancer Institute. 105:654-663. 2013
- Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial. Journal of Clinical Oncology. 31:1398-1404. 2013
- Analysis of Regional Timelines To Set Up a Global Phase III Clinical Trial in Breast Cancer: The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Experience. Oncologist. 18:134-140. 2013
- Endocrine Therapy for Postmenopausal Women with Hormone Receptor–Positive her2–Negative Advanced Breast Cancer after Progression or Recurrence on Nonsteroidal Aromatase Inhibitor Therapy: A Canadian Consensus Statement. Current Oncology. 20:48-61. 2013
- Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole. Annals of Oncology. 24:355-361. 2013
- Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. The Lancet Oncology. 14:88-96. 2013
- Bone-Targeted Agents and Skeletal-Related Events in Breast Cancer Patients with Bone Metastases: The State of the Art. Current Oncology. 19:259-268. 2012
- Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials. Cancer Treatment Reviews. 38:673-688. 2012
- Response. Journal of the National Cancer Institute. 104:1268-1268. 2012
- A 50-Gene Intrinsic Subtype Classifier for Prognosis and Prediction of Benefit from Adjuvant Tamoxifen. Clinical Cancer Research. 18:4465-4472. 2012
- Personalized Medicine: What Exactly Is It and Can We Truly Measure It?. Journal of Clinical Oncology. 30:2173-2174. 2012
- ABC 1 (1st International consensus guidelines for advanced breast cancer): A positive step. Breast. 21:225-226. 2012
- Adjuvant Endocrine Therapy for Breast Cancer: A Commentary Kathleen I. Pritchard Article Reviewed. Oncology. 26:568-570. 2012
- Adjuvant endocrine therapy for breast cancer: a commentary.. Oncology. 26:568-570. 2012
- Update of the Oxford Overview: New Insight and Perspectives in the Era of Personalized Medicine. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 71-79. 2012
- Prospective Study of 2-[18F]Fluorodeoxyglucose Positron Emission Tomography in the Assessment of Regional Nodal Spread of Disease in Patients With Breast Cancer: An Ontario Clinical Oncology Group Study. Journal of Clinical Oncology. 30:1274-1279. 2012
- Reply to P. Ameri et al. Journal of Clinical Oncology. 30:1396-1396. 2012
- Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial. Clinical Cancer Research. 18:2402-2412. 2012
- CYP2D6 Genotype as a Marker for Benefit of Adjuvant Tamoxifen in Postmenopausal Women: Lessons Learned. Journal of the National Cancer Institute. 104:427-428. 2012
- Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. European Journal of Cancer. 48:475-481. 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine. 366:520-529. 2012
- Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. The Lancet. 379:432-444. 2012
- TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients. Breast Cancer Research and Treatment. 132:225-234. 2012
- Insulin- and Obesity-Related Variables in Early-Stage Breast Cancer: Correlations and Time Course of Prognostic Associations. Journal of Clinical Oncology. 30:164-171. 2012
- Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial. Breast Cancer Research and Treatment. 131:541-551. 2012
- First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study. Oncology. 82:218-227. 2012
- Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer. Journal of Clinical Oncology. 29:4755-4762. 2011
- Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines. BMC Medical Genomics. 4:18. 2011
- Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold?. Annals of Oncology. 22:2387-2393. 2011
- Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. The Lancet. 378:1707-1716. 2011
- Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial. Breast Cancer Research and Treatment. 130:133-143. 2011
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. The Lancet Oncology. 12:1134-1142. 2011
- Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14. Journal of Clinical Oncology. 29:3869-3876. 2011
- Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14. Journal of Clinical Oncology. 29:3605-3610. 2011
- Reply to C. McCowan et al. Journal of Clinical Oncology. 29:3492-3493. 2011
- Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. Breast Cancer Research and Treatment. 128:401-409. 2011
- Estrogen receptor: is it predictive for response to cytotoxic as well as hormonal therapy?. Breast Cancer Research and Treatment. 127:587-588. 2011
- Long-Term Follow-Up of Women in Trials of Adjuvant Therapy for Breast Cancer: Is It Still Important?. Journal of Clinical Oncology. 29:1651-1652. 2011
- Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. Breast Cancer Research and Treatment. 126:295-310. 2011
- First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Annals of Oncology. 22:595-602. 2011
- Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. The Lancet Oncology. 12:236-244. 2011
- Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Research and Treatment. 126:215-220. 2011
- The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Breast Diseases. 22:210-213. 2011
- Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors. Journal of Clinical Oncology. 28:5147-5152. 2010
- Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?. Breast Cancer Research. 12:S18. 2010
- Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors. Journal of Clinical Oncology. 28:4674-4682. 2010
- Strengthening Advocacy Messages to Improve Child Nutrition. Breastfeeding Medicine. 5:263-264. 2010
- Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Research and Treatment. 123:453-461. 2010
- A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium. Oncologist. 15:810-818. 2010
- Optimizing the Management of her2-Positive Early Breast Cancer: The Clinical Reality. Current Oncology. 17:20-33. 2010
- Optimizing the management of HER2-positive early breast cancer: the clinical reality. Current Oncology. 17:154-167. 2010
- Obesity and Hormone Therapy in Breast Cancer: An Unfinished Puzzle. Journal of Clinical Oncology. 28:3405-3407. 2010
- Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Annals of Oncology. 21:1246-1253. 2010
- High levels of uPA and PAI-1 predict a good response to anthracyclines. Breast Cancer Research and Treatment. 121:625-626. 2010
- Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer. Oncologist. 15:457-465. 2010
- Review of the Clinical Studies Using the 21-Gene Assay. Oncologist. 15:447-456. 2010
- Disseminated Tumor Embolism From Breast Cancer Leading to Multiorgan Failure. Journal of Clinical Oncology. 28:e180-e183. 2010
- Adjuvant hormonal therapy for premenopausal breast cancer: incorporating clinical experience.. Oncology. 24:332-340. 2010
- Optimizing the Delivery of Targeted Research: An Opportunity for Comparative Effectiveness Research. Journal of Clinical Oncology. 28:1089-1091. 2010
- Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response. Journal of Clinical Oncology. 28:723-730. 2010
- Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. The BMJ. 340:c693-c693. 2010
- A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12). Annals of Oncology. 21:283-290. 2010
- Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer. Cancer Treatment Reviews. 36:54-62. 2010
- Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. Breast Cancer Research and Treatment. 119:347-356. 2010
- Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer. Journal of Clinical Oncology. 28:77-82. 2010
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. The Lancet Oncology. 11:55-65. 2010
- Response: Re: Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. Journal of the National Cancer Institute. 101:1736-1737. 2009
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. The Lancet. 374:2055-2063. 2009
- Tailored targeted therapy for all: a realistic and worthwhile objective against. Breast Cancer Research. 11:S8. 2009
- Management of HER2-positive breast cancer in Asia: consensus statement from the Asian Oncology Summit 2009. The Lancet Oncology. 10:1077-1085. 2009
- Commentary: Anthracyclines in Early-Stage Breast Cancer: Is It the End of an Era?. Oncologist. 14:959-962. 2009
- Bisphosphonates for prevention of bone loss in women with early breast cancer. Clinical Respiratory Journal. 2009
- The Role of Neoadjuvant her2-Targeted Therapies in her2-Overexpressing Breast Cancers. Current Oncology. 16:48-57. 2009
- Are HER2 and TOP2A Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?. Journal of Clinical Oncology. 27:3875-3876. 2009
- Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer. Journal of Clinical Oncology. 27:3757-3763. 2009
- The Role of her2-Targeted Therapies in Women with her2-Overexpressing Metastatic Breast Cancer. Current Oncology. 16:25-35. 2009
- The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer. Current Oncology. 16:235-245. 2009
- American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. Journal of Clinical Oncology. 27:3235-3258. 2009
- American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. JCO Oncology Practice. 5:196-199. 2009
- Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. Journal of the National Cancer Institute. 101:644-650. 2009
- High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Research and Treatment. 114:517-525. 2009
- Adjuvant targeted therapy in early breast cancer. Cancer. 115:1154-1168. 2009
- Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?. Breast Cancer Research and Treatment. 114:387-389. 2009
- Endocrine Therapy with Selective Estrogen Receptor Modulators (SERMs) and Aromatase Inhibitors in the Prevention and Adjuvant Therapy Settings. Cancer Treatment and Research. 147:1-29. 2009
- Guidelines, Consensus Conferences and Overviews (Meta-analysis). Cancer Treatment and Research. 151:63-76. 2009
- Ovarian suppression/ablation in premenopausal ER-positive breast cancer patients. Issues and recommendations.. Oncology. 23:27-33. 2009
- Preferential Killing of Breast Tumor Initiating Cells by N,N-Diethyl-2-[4-(Phenylmethyl)Phenoxy]Ethanamine/Tesmilifene. Clinical Cancer Research. 15:119-130. 2009
- Endocrine symptoms to predict risk of recurrence?. The Lancet Oncology. 9:1117-1119. 2008
- Insulin-Lowering Effects of Metformin in Women with Early Breast Cancer. Clinical Breast Cancer. 8:501-505. 2008
- Who should participate in clinical trials and who not? Can clinical trials be made more efficient and effective?. Breast Cancer Research. 10:S23. 2008
- Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer. Journal of Clinical Oncology. 26:5465-5476. 2008
- Adjuvant/neoadjuvant trastuzumab therapy in women with HER-2/neu-overexpressing breast cancer: A systematic review. Cancer Treatment Reviews. 34:539-557. 2008
- Identification of Cancer Care and Protocol Characteristics Associated With Recruitment in Breast Cancer Clinical Trials. Journal of Clinical Oncology. 26:4458-4465. 2008
- Response. Journal of the National Cancer Institute. 100:1117-1118. 2008
- Lymphedema in women with breast cancer: characteristics of patients screened for a randomized trial. Breast Cancer Research and Treatment. 110:337-342. 2008
- Antihormone Therapy in Recurrent Metastatic Breast Cancer. Journal of the American Medical Association (JAMA). 299:2745-2745. 2008
- In Reply. Journal of Clinical Oncology. 26:2596-2597. 2008
- HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Research and Treatment. 109:209-229. 2008
- Intent-to-treat analysis of the placebo-controlled trial of letrozole for extended adjuvant therapy in early breast cancer: NCIC CTG MA.17. Annals of Oncology. 19:877-882. 2008
- Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17. Journal of Clinical Oncology. 26:1956-1964. 2008
- Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen. Journal of Clinical Oncology. 26:1948-1955. 2008
- Should Observational Studies Be a Thing of the Past?. Journal of the National Cancer Institute. 100:451-452. 2008
- Aromatase inhibitors in adjuvant therapy for hormone receptor positive breast cancer: A systematic review. Cancer Treatment Reviews. 34:157-174. 2008
- HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy. Journal of Clinical Oncology. 26:736-744. 2008
- Endocrine and targeted manipulation of breast cancer: Summary statement for the Sixth Cambridge Conference. Cancer. 112:673-678. 2008
- Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials. The Lancet. 371:29-40. 2008
- Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16. Journal of Clinical Oncology. 26:37-43. 2008
- Adjuvant and extended adjuvant use of aromatase inhibitors: Reducing the risk of recurrence and distant metastasis. Breast. 16:1-9. 2007
- A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes. Annals of Oncology. 18:1646-1651. 2007
- Role of Gonadotropin-Releasing Hormone Analog in the Management of Male Metastatic Breast Cancer Is Uncertain. Journal of Clinical Oncology. 25:3787-3787. 2007
- Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clinical Cancer Research. 13:4429-4434. 2007
- Risk of chemotherapy induced menopause: More detailed data will lead to improved quality of life. European Journal of Cancer. 43:1644-1645. 2007
- Bisphosphonates: are they standard of care for the treatment of breast cancer?. British Journal of Cancer. 96:1781-1782. 2007
- Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System. Journal of Clinical Oncology. 25:2127-2132. 2007
- Tamoxifen-Associated Hot Flashes in Women. Supportive Cancer Therapy. 4:152-156. 2007
- Adjuvant Therapy for Breast Cancer: We Are Solving the Puzzle, But Pieces Are Still Missing. Journal of the National Cancer Institute. 99:494-495. 2007
- Have we been guilty of ageism in the primary treatment of breast cancer?. British Journal of Cancer. 96:1011-1012. 2007
- Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non–Small-Cell Lung Cancer With Disease-Related Anemia. Journal of Clinical Oncology. 25:1027-1032. 2007
- Selective Application of Axillary Node Dissection in Elderly Women with Early Breast Cancer. Annals of Surgical Oncology. 14:652-659. 2007
- Therapeutic options for the management of hot flashes in breast cancer survivors: An evidence-based review. Clinical Therapeutics. 29:230-241. 2007
- Therapeutic options for the management of hot flashes in breast cancer survivors: an evidence-based review.. Clinical Therapeutics. 29:230-241. 2007
- Quality of Life Analyses in a Clinical Trial of DPPE (tesmilifene) Plus Doxorubicin Versus Doxorubicin in Patients with Advanced or Metastatic Breast Cancer: NCIC CTG Trial MA.19. Breast Cancer Research and Treatment. 100:263-271. 2006
- Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations. Journal of the National Comprehensive Cancer Network : JNCCN. 4:971-979. 2006
- Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy. Journal of Clinical Oncology. 24:4895-4900. 2006
- Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Research and Treatment. 99:295-300. 2006
- Symptomatic venous thromboembolism after orthognathic operations: An audit. British Journal of Oral and Maxillofacial Surgery. 44:389-392. 2006
- Anthracyclines in Early Breast Cancer. New England Journal of Medicine. 355:845-846. 2006
- Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17. Journal of Clinical Oncology. 24:3629-3635. 2006
- Biological Significance of Occult Micrometastases in Histologically Negative Axillary Lymph Nodes in Breast Cancer Patients Using the Recent American Joint Committee on Cancer Breast Cancer Staging System. Breast Journal. 12:294-301. 2006
- Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact?. Annals of Oncology. 17:1035-1036. 2006
- HER2and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. New England Journal of Medicine. 354:2103-2111. 2006
- Body radiation exposure in breast cancer radiotherapy: Impact of breast IMRT and virtual wedge compensation techniques. International Journal of Radiation Oncology Biology Physics. 65:52-58. 2006
- Trends in endocrine therapy and chemotherapy for early breast cancer: a focus on the premenopausal patient. Journal of Cancer Research and Clinical Oncology. 132:275-286. 2006
- NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 4:S1-26. 2006
- Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care. Journal of Clinical Oncology. 24:848-855. 2006
- Managing Patients on Endocrine Therapy: Focus on Quality-of-Life Issues. Clinical Cancer Research. 12:1056s-1060s. 2006
- The extended adjuvant NCIC CTG MA.17 trials: Initial and rerandomization studies. Breast. 15:14-20. 2006
- Ascertaining Prognosis for Breast Cancer in Node-Negative Patients with Innovative Survival Analysis. Breast Journal. 12:37-47. 2006
- Cardiovascular Health and Aromatase Inhibitors. Drugs. 66:1727-1740. 2006
- The Early Breast Cancer Trialists Collaborative Group (EBCTCG) Process: Is it Still Relevant in 2006?. Breast Care. 1:338-339. 2006
- Obesity and cancer: The risks, science, and potential management strategies: Commentary. Oncology. 19. 2005
- Adjuvant endocrine therapies for pre-/perimenopausal women. Breast. 14:547-554. 2005
- Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 366:2087-2106. 2005
- The Global Breast Cancer Burden: Variations in Epidemiology and Survival. Clinical Breast Cancer. 6:391-401. 2005
- Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. The Lancet Oncology. 6:886-898. 2005
- Serum Lipids and Outcome of Early-stage Breast Cancer: Results of a Prospective Cohort Study. Breast Cancer Research and Treatment. 94:135-144. 2005
- A review of exemestane in the management of breast cancer. Expert Opinion on Pharmacotherapy. 6:2353-2363. 2005
- Adjuvant hormonal therapy in early breast cancer - The Kumar/Leonard article reviewed. Oncology. 19:1436-+. 2005
- Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women. Journal of Clinical Oncology. 23:6931-6940. 2005
- Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Annals of Oncology. 16:1569-1583. 2005
- The Kumar/Leonard article reviewed. Oncology. 19:1436-1441. 2005
- Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. Journal of the National Cancer Institute. 97:1262-1271. 2005
- Incidence and Prognostic Impact of Amenorrhea During Adjuvant Therapy in High-Risk Premenopausal Breast Cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA.5. Journal of Clinical Oncology. 23:6002-6008. 2005
- Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer?. Journal of Clinical Oncology. 23:6037-6042. 2005
- Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer. Journal of Clinical Oncology. 23:5542-5551. 2005
- Aromatase Inhibitors in Adjuvant Therapy of Breast Cancer: Before, Instead of, or Beyond Tamoxifen. Journal of Clinical Oncology. 23:4850-4852. 2005
- Estimating per patient funding for cancer clinical trials: An Ontario based survey. Contemporary Clinical Trials. 26:421-429. 2005
- Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. Journal of Clinical Oncology. 23:5166-5170. 2005
- The McTiernan article reviewed. Oncology. 19:881-882. 2005
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. The Lancet. 365:1687-1717. 2005
- Architectural constraint in fruit production of Crotalaria spectabilis (Fabaceae). Plant Species Biology. 20:41-46. 2005
- Clinical trial update: National Cancer Institute of Canada. Breast Cancer Research. 7:48-51. 2005
- Endocrinology and hormone therapy in breast cancer: Endocrine therapy in premenopausal women. Breast Cancer Research. 7:70-76. 2005
- Survey of oral rehabilitation in a consecutive series of 130 patients treated by primary resection for oral and oropharyngeal squamous cell carcinoma. British Journal of Oral and Maxillofacial Surgery. 43:23-30. 2005
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004. Journal of Clinical Oncology. 23:619-629. 2005
- American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. Journal of Clinical Oncology. 23:619-629. 2005
- Prognostic factors affecting the natural history of node-negative breast cancer. Breast Cancer Research and Treatment. 89:35-45. 2005
- Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables. Journal of Clinical Oncology. 22:4184-4192. 2004
- Is expert breast pathology assessment necessary for the management of ductal carcinoma in situ?. Breast Cancer Research and Treatment. 87:265-272. 2004
- The Ravdin article reviewed. Oncology. 18:1394-1394. 2004
- Phase III study of N, N-Diethyl-2-[4-(Phenylmethyl) Phenoxyl] Ethanamine (BMS-2173801-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA-19. Women's Oncology Review. 4:125-126. 2004
- The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. Women's Oncology Review. 4:131-132. 2004
- Is exercise effective in reducing the risk of breast cancer in postmenopausal women?. CANADIAN MEDICAL ASSOCIATION JOURNAL. 170:787-787. 2004
- Phase III Study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. Journal of Clinical Oncology. 22:269-276. 2004
- Role of aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer. Current Oncology. 11:41-52. 2004
- The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer. Journal of Clinical Oncology. 22:86-96. 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer. New England Journal of Medicine. 349:1793-1802. 2003
- Risk of Acute Leukemia Following Epirubicin-Based Adjuvant Chemotherapy: A Report From the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 21:3066-3071. 2003
- American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting. Journal of Clinical Oncology. 21:2597-2599. 2003
- Diet and Breast Cancer: Evidence That Extremes in Diet Are Associated With Poor Survival. Journal of Clinical Oncology. 21:2500-2507. 2003
- Oestrogen receptor downregulation: an opportunity for extending the window of endocrine therapy in advanced breast cancer. Annals of Oncology. 14:1017-1025. 2003
- Adjuvant therapy for early breast cancer: where do we stand today?. Medscape journal of medicine. 5:17. 2003
- CORRESPONDENCE. Journal of Clinical Oncology. 21:2445-2446. 2003
- Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data. Journal of Clinical Oncology. 21:1944-1951. 2003
- Hormone Replacement Therapy after Treatment for Breast Cancer: Physicians' Attitudes towards Randomized Trials. Breast Cancer Research and Treatment. 79:213-223. 2003
- Helping Patients Make Informed Choices: A Randomized Trial of a Decision Aid for Adjuvant Chemotherapy in Lymph Node-Negative Breast Cancer. Journal of the National Cancer Institute. 95:581-587. 2003
- Optimal Chemotherapy for Women With Breast Cancer: The Plot Thickens. Journal of Clinical Oncology. 21:963-964. 2003
- Final Results of a Randomized Phase III Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With a Dose-Intensified Epirubicin and Cyclophosphamide + Filgrastim as Neoadjuvant Treatment in Locally Advanced Breast Cancer: An EORTC-NCIC-SAKK Multicenter Study. Journal of Clinical Oncology. 21:843-850. 2003
- neu/erbB-2 Overexpression and Response to Hormonal Therapy in Premenopausal Women in the Adjuvant Breast Cancer Setting: Will It Play in Peoria? Part II. Journal of Clinical Oncology. 21:399-400. 2003
- A Comparison of Risk Perception and Psychological Morbidity in Women with Ductal Carcinoma in situ and Early Invasive Breast Cancer. Breast Cancer Research and Treatment. 77:285-293. 2003
- Endocrine therapy of advanced disease: analysis and implications of the existing data.. Clinical Cancer Research. 9:460S-467S. 2003
- Role of taxanes in the management of metastatic breast cancer. Current Oncology. 10:68-83. 2003
- Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.. Clinical Cancer Research. 9:443S-446S. 2003
- Adjuvant Therapy for Premenopausal Women With Breast Cancer: Is It Time for Another Paradigm Shift?. Journal of Clinical Oncology. 20:4611-4614. 2002
- Hormonal replacement therapy in breast cancer. Annals of Oncology. 13:73-80. 2002
- American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002. Journal of Clinical Oncology. 20:3317-3327. 2002
- Insulin-like growth factor binding proteins 1 and 3 and breast cancer outcomes. Breast Cancer Research and Treatment. 74:65-76. 2002
- Native low-density lipoprotein induces endothelial nitric oxide synthase dysfunction: role of heat shock protein 90 and caveolin-1. Free Radical Biology and Medicine. 33:52-62. 2002
- Phase III Randomized Trial of Droloxifene and Tamoxifen As First-Line Endocrine Treatment of ER/PgR-Positive Advanced Breast Cancer. Breast Cancer Research and Treatment. 73:161-175. 2002
- Clinical practice guidelines for the care and treatment of breast cancer: 14. The role of hormone replacement therapy in women with a previous diagnosis of breast cancer.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 166:1017-1022. 2002
- Screening mammography: setting the record straight. The Lancet. 359:439-440. 2002
- Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncologyclinic. Annals of Oncology. 13:12-15. 2002
- Current management of menopausal symptoms in cancer patients - The Barton/Loprinzi/Gostout article reviewed. Oncology. 16:75-76. 2002
- Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study. Journal of Clinical Oncology. 20:42-51. 2002
- Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study. Journal of Clinical Oncology. 20:42-51. 2002
- To the editor. Journal of Obstetrics and Gynaecology Canada. 24:11-11. 2002
- The Effect of Group Psychosocial Support on Survival in Metastatic Breast Cancer. New England Journal of Medicine. 345:1719-1726. 2001
- Breast Cancer Prevention with Selective Estrogen Receptor Modulators. Annals of the New York Academy of Sciences. 949:89-98. 2001
- Future directions panel discussion. Clinical Cancer Research. 7:4411S-4412S. 2001
- The role of tamoxifen and aromatase inhibitors/inactivators in postmenopausal patients.. Clinical Cancer Research. 7:4356s-4359s. 2001
- Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria?. Journal of Clinical Oncology. 19:3795-3797. 2001
- Hormone Replacement in Women with a History of Breast Cancer. Oncologist. 6:353-362. 2001
- Raloxifene: handle with care.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 165:151-153. 2001
- A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis. Cancer. 92:23-29. 2001
- Baseline staging tests in primary breast cancer: a practice guideline.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 164:1439-1444. 2001
- Systematic overview of the evidence for brachytherapy in clinically localized prostate cancer.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 164:975-981. 2001
- The role of hormone replacement therapy in women with a previous diagnosis of breast cancer and a review of possible alternatives. Annals of Oncology. 12:301-310. 2001
- Can improved communication increase patient participation in randomised clinical trials?. European Journal of Cancer. 37:297-299. 2001
- Raloxifene: Handle with care [3]. CANADIAN MEDICAL ASSOCIATION JOURNAL. 165:149-150. 2001
- Current and future directions in medical therapy for breast carcinoma. Cancer. 88:3065-3072. 2000
- Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. Journal of Clinical Oncology. 18:2385-2394. 2000
- Endocrine therapy for breast cancer.. Oncology. 14:483-492. 2000
- 'Two solitudes' or 'A mouse in bed with two elephants'. Current Oncology. 7:3-4. 2000
- Adjuvant hormonal therapy. Seminars in Breast Disease. 3:81-89. 2000
- High Dose Therapy with Stem Cell Support for Breast Cancer: The Jury Is Still Out. Cancer Treatment and Research. 103:115-136. 2000
- Should Tamoxifen Be Used to Treat Premenopausal Women with Breast Cancer?. Cancer Investigation. 18:685-686. 2000
- Tamoxifen for breast cancer prevention. European Journal of Cancer. 36:148-150. 2000
- The use of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer and methods of assessing HER2/neu status - An evidence summary. Current Oncology. 7:242-251. 2000
- Use of capecitabine in stage IV breast cancer: An evidence summary. Current Oncology. 7:84-90. 2000
- Use of vinorelbine in stage IV breast cancer: An evidence summary. Current Oncology. 7:24-28. 2000
- Tamoxifen added to adjuvant chemotherapy in premenopausal women with early breast cancer: is it standard practice or still a subject for study?. European Journal of Cancer. 35:1625-1627. 1999
- Risk of Menopause During the First Year After Breast Cancer Diagnosis. Journal of Clinical Oncology. 17:2365-2365. 1999
- Treatment of estrogen deficiency symptoms in women surviving breast cancer - Part 6: Executive summary and consensus statement - Proceedings of a conference held at the Boar's Head Inn - Charlottesville, Virginia, September 21-23, 1997. Oncology. 13:859-+. 1999
- The fox guarding the clinical trial: internal vs. external validity in randomized studies. Psycho-Oncology. 8:275-275. 1999
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 4: Urogenital atrophy, vasomotor instability, sleep disorders, and related symptoms.. Oncology. 13:551-passim. 1999
- Treatment of estrogen deficiency symptoms in women surviving breast cancer - Part 3: Prevention of osteoporosis and CV effects of estrogens and antiestrogens - Proceedings of a conference held at the Boar's Head Inn Charlottesville, Virginia - September 21-23, 1997. Oncology. 13:397-+. 1999
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 2: Hormone replacement therapy and breast cancer.. Oncology. 13:245-passim. 1999
- Adjuvant Treatment and Onset of Menopause Predict Weight Gain After Breast Cancer Diagnosis. Journal of Clinical Oncology. 17:120-120. 1999
- The role of adjuvant systemic therapy in node-negative breast cancer. Current Oncology. 6:78-89. 1999
- Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 1: Defining the problem. Proceedings of a conference held at the Boar's Head Inn Charlottesville, Virginia. September 21-23, 1997.. Oncology. 13:109-115. 1999
- Use of biphosphonates in patients with bone metastases from breast cancer. Current Oncology. 6:144-154. 1999
- Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer - In reply. Journal of Clinical Oncology. 16:3917-3917. 1998
- Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer.. Journal of Clinical Oncology. 16:3916-3917. 1998
- Introduction. Obstetrical and Gynecological Survey. 53:1S-1S. 1998
- Polychemotherapy for early breast cancer: an overview of the randomised trials. The Lancet. 352:930-942. 1998
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. Journal of Clinical Oncology. 16:2651-2658. 1998
- Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.. Journal of Clinical Oncology. 16:2651-2658. 1998
- Is tamoxifen effective in prevention of breast cancer?. The Lancet. 352:80-81. 1998
- Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.. Cancer Prevention and Control. 2:140-146. 1998
- Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen.. Clinical Cancer Research. 4:1451-1457. 1998
- Treatment of Estrogen Deficiency Symptoms in Women Surviving Breast Cancer. Journal of Clinical Endocrinology and Metabolism (JCEM). 83:1993-2000. 1998
- Multidisciplinary weight management in locoregional breast cancer: results of a phase II study. Breast Cancer Research and Treatment. 48:53-64. 1998
- Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback.. Journal of Clinical Oncology. 16:1226-1231. 1998
- High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.. Journal of Clinical Oncology. 16:800-802. 1998
- Adjuvant systemic therapy for women with node-positive breast cancer. CANADIAN MEDICAL ASSOCIATION JOURNAL. 158:S52-S64. 1998
- Estrogen/Hormone Replacement Therapy and the Etiology of Breast Cancer. Recent Results in Cancer Research. 152:22-31. 1998
- GnRH Analogues and Ovarian Ablation: Their Integration in the Adjuvant Strategy. Recent Results in Cancer Research. 152:285-297. 1998
- New initiatives in the management of recurrent breast cancer. Current Oncology. 5:188-194. 1998
- Ovarian ablation as adjuvant therapy for early-stage breast cancer. Cancer Treatment and Research. 94:159-180. 1998
- Recent reports in breast cancer. Current Oncology. 5:143-147. 1998
- Pamidronate reduced skeletal complications in patients with breast cancer and lytic bone metastases. Evidence-Based Medicine. 2:73. 1997
- Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer. Cancer Chemotherapy and Pharmacology. 41:53-60. 1997
- Breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making.. Journal of Clinical Oncology. 15:3192-3200. 1997
- Attitudes of Canadian Oncology Practitioners Toward Psychosocial Interventions in Clinical and Research Settings in Women With Breast Cancer. Psycho-Oncology. 6:178-189. 1997
- Attitudes of Canadian Oncology Practitioners Toward Psychosocial Interventions in Clinical and Research Settings in Women With Breast Cancer. Psycho-Oncology. 6:178-189. 1997
- A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1. Breast Cancer Research and Treatment. 44:211-215. 1997
- An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Research and Treatment. 44:201-210. 1997
- Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.. Journal of Clinical Oncology. 15:2302-2311. 1997
- Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.. Journal of Clinical Oncology. 15:1897-1905. 1997
- The association between population-based treatment guidelines and adjuvant therapy for node-negative breast cancer. British Journal of Cancer. 75:1534-1542. 1997
- Breast cancer: the real challenge. The Lancet. 349:S24-S26. 1997
- Decreased levels of the cell-cycle inhibitor p27Kip1 protein: Prognostic implications in primary breast cancer. Nature Medicine. 3:227-230. 1997
- Patterns of initial management of node-negative breast cancer in two Canadian provinces. British Columbia/Ontario Working Group.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 156:25-35. 1997
- The clinical practice guideline: an evolving health care technology.. Cancer Prevention and Control. 1:7-8. 1997
- Ovarian ablation in early breast cancer: overview of the randomised trials. The Lancet. 348:1189-1196. 1996
- An improved statistical approach: Can it clarify the role of new prognostic factors for breast cancer?. European Journal of Cancer. 32:1949-1956. 1996
- Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.. Journal of Clinical Oncology. 14:2731-2737. 1996
- Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study.. Journal of Clinical Oncology. 14:2709-2712. 1996
- Postmenopausal breast cancer: is the short-term pain worth the long-term gain?. The Lancet. 347:1057-1058. 1996
- An investigation of cut-points for primary breast cancer oestrogen and progesterone receptor assays. Journal of Steroid Biochemistry and Molecular Biology. 57:323-328. 1996
- Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?. Journal of Clinical Oncology. 14:997-1006. 1996
- Human Antibodies with Sub-nanomolar Affinities Isolated from a Large Non-immunized Phage Display Library. Nature Biotechnology. 14:309-314. 1996
- Randomized trial of group psychosocial support in metastatic breast cancer: the BEST study. Cancer Treatment Reviews. 22:91-96. 1996
- Sex Hormones and Breast Cancer: The Issue of Hormone Replacement. Recent Results in Cancer Research. 140:285-293. 1996
- Effects of Radiotherapy and Surgery in Early Breast Cancer — An Overview of the Randomized Trials. New England Journal of Medicine. 333:1444-1456. 1995
- The Henrietta Banting Breast Centre database: A model for clinical research utilizing a hospital-based inception cohort. Journal of Clinical Epidemiology. 48:779-786. 1995
- The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.. Journal of Clinical Oncology. 13:502-512. 1995
- Caldesmon mRNA splicing and isoform expression in mammalian smooth-muscle and non-muscle tissues. Biochemical Journal. 305:445-450. 1995
- Current status of Vinorelbine for breast cancer. Commentaries. Oncology. 9:774-779. 1995
- Menopausal estrogen replacement therapy in women with breast cancer. Cancer. 75:1-3. 1995
- Clinical cooperative trials of the National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.. Cancer. 74:1150-1155. 1994
- Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. The Lancet. 343:886-889. 1994
- Induction of cyclooxygenase-2 in rat vascular smooth muscle cells in vitro and in vivo.. Journal of Biological Chemistry. 269:8504-8509. 1994
- Location of two contact sites between human smooth muscle caldesmon and Ca(2+)-calmodulin.. Journal of Biological Chemistry. 269:8134-8139. 1994
- Adjuvant systemic therapy for breast cancer: a tale of relapse and survival. The Lancet. 343:370-371. 1994
- Droloxifene, a new antiestrogen: Its role in metastatic breast cancer. Breast Cancer Research and Treatment. 31:83-94. 1994
- Informed consent in compliance studies.. Journal of Clinical Oncology. 11:2457-2458. 1993
- Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.. Journal of Clinical Oncology. 11:1241-1244. 1993
- The standardization of estrogen receptors. Journal of Steroid Biochemistry and Molecular Biology. 45:367-373. 1993
- Ondansetron Compared with Dexamethasone and Metoclopramide as Antiemetics in the Chemotherapy of Breast Cancer with Cyclophosphamide, Methotrexate, and Fluorouracil. New England Journal of Medicine. 328:1081-1084. 1993
- A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer. European Journal of Cancer. 29:37-43. 1993
- The Ca2+-Sensitizing Component of Smooth Muscle Thin Filaments: Properties of Regulatory Factors That Interact with Caldesmon. Biochemical and Biophysical Research Communications. 190:668-673. 1993
- The Canadian Experience with Intensive Fluorouracil, Epirubicin and Cyclophosphamide in Patients with Early Stage Breast Cancer. Drugs. 45:51-59. 1993
- A comparison of all-subset Cox and accelerated failure time models with Cox step-wise regression for node-positive breast cancer. Breast Cancer Research and Treatment. 22:263-272. 1992
- METAANALYSIS - ITS APPLICATION TO CLINICAL MEDICINE. DIAGNOSTIC ONCOLOGY. 2:80-89. 1992
- Phase II study of oral menogaril as first line chemotherapy for advanced breast cancer: A National Cancer Institute of Canada Clinical Trials Group Study. Annals of Oncology. 3:201-204. 1992
- Adjuvant endocrine therapy of breast cancer. Cancer Treatment and Research. 60:69-114. 1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. The Lancet. 339:71-85. 1992
- Ca2+-dependent regulation of vascular smooth-muscle caldesmon by S.100 and related smooth-muscle proteins. Biochemical Journal. 277:819-824. 1991
- Introduction. Blood Coagulation and Fibrinolysis. 14:vii-vii. 1991
- THERAPEUTIC ADVANTAGES OF DROLOXIFENE, A NEW ANTIESTROGEN, IN BREAST-CANCER - PROCEEDINGS OF THE SATELLITE SYMPOSIUM DROLOXIFENE, A NEW ANTIESTROGEN WITH THERAPEUTIC ADVANTAGES HELD DURING THE 15TH INTERNATIONAL CANCER CONGRESS, HAMBURG, FRG, AUGUST 18, 1990 - SUMMARY. American Journal of Clinical Oncology. 14:S62-S63. 1991
- Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second-line treatment of recurrent breast cancer.. Seminars in Oncology. 17:52-62. 1990
- Activity of intravenous menogaril in patients with previously untreated metastatic breast cancer. Investigational New Drugs. 8:283-287. 1990
- Chemotherapy and endocrine therapy in metastatic disease.. Current Opinion in Oncology. 1:324-332. 1989
- The Use of Endocrine Therapy. Hematology/Oncology Clinics of North America. 3:765-805. 1989
- Systemic adjuvant therapy for node-negative breast cancer.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 141:381-387. 1989
- ADJUVANT THERAPY FOR NODE-NEGATIVE BREAST-CANCER. New England Journal of Medicine. 321:471-471. 1989
- Systemic Adjuvant Therapy for Node-Negative Breast Cancer: Proven or Premature?. ACP journal club. 111:1-1. 1989
- Ca2+-calmodulin binding to caldesmon and the caldesmon-actin-tropomyosin complex. Its role in Ca2+ regulation of the activity of synthetic smooth-muscle thin filaments. Biochemical Journal. 257:839-843. 1989
- Screening for Endometrial Cancer: Is It Effective?. ACP journal club. 110:177-177. 1989
- Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast Cancer. New England Journal of Medicine. 319:1681-1692. 1988
- Ca2+ regulation of the thin filaments: biochemical mechanism and physiological role. Biochemical Society Transactions. 16:494-497. 1988
- Estrogen and progesterone receptor content of primary and secondary breast carcinoma: Influence of time and treatment. European Journal of Cancer. 23:819-826. 1987
- Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma.. Journal of Clinical Oncology. 5:635-640. 1987
- Current status of adjuvant endocrine therapy for resectable breast cancer.. Seminars in Oncology. 14:23-33. 1987
- The mechanism of Ca2+ regulation of vascular smooth muscle thin filaments by caldesmon and calmodulin.. Journal of Biological Chemistry. 262:116-122. 1987
- Phase II study of lonidamine in patients with metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group Study.. Journal of the National Cancer Institute. 70:1305-1310. 1986
- Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma.. Cancer Research. 46:3152-3156. 1986
- The frequency of malignant neoplasms in patients with polymyositis-dermatomyositis. A controlled study. JAMA Internal Medicine. 145:1835-1839. 1985
- A phase II study of spirogermanium in patients with metastatic malignant melanoma. Investigational New Drugs. 3:303-305. 1985
- CLINICAL USES OF BAYESIAN PROBABILITY. The Lancet. 325:993-994. 1985
- CLINICAL USES OF BAYESIAN PROBABILITY. The Lancet. 1:993-993. 1985
- The efficacy of bone scanning in the follow-up of patients with operable breast cancer. Breast Cancer Research and Treatment. 4:303-307. 1984
- Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer.. Journal of the National Cancer Institute. 68:1421-1422. 1984
- Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung.. Journal of Clinical Oncology. 2:294-304. 1984
- BCG in the treatment of cancer.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 129:1173. 1983
- Treatment of Advanced Breast Cancer. New England Journal of Medicine. 305:1649-1650. 1981
- Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma.. Journal of the National Cancer Institute. 65:947-954. 1981
- The influence of tamoxifen on menstruation and serum hormone levels in premenopausal patients with metastatic breast cancer. Annals of the Royal College of Physicians and Surgeons of Canada. 14. 1981
- The influence of tamoxifen on menstruation and serum hormone levels in premenopausal patients with metastatic breast cancer. Proceedings of the American Association for Cancer Research. Vol. 22:574. 1981
- The role of tamoxifen in premenopausal women with carcinoma of the breast: An update. Annals of the Royal College of Physicians and Surgeons of Canada. 14. 1981
- DTIC therapy in metastatic malignant melanoma: a simplified dose schedule.. Journal of the National Cancer Institute. 64:1123-1126. 1980
- Tamoxifen therapy in premenopausal patients with metastatic breast cancer.. Journal of the National Cancer Institute. 64:787-796. 1980
- Phenytoin-associated reversible red cell aplasia.. CANADIAN MEDICAL ASSOCIATION JOURNAL. 121:1491-1493. 1979
- A flow system adaptation of the SCM test for detection of lymphocyte response in patients with recurrent breast cancer. Clinical Immunology. 13:171-181. 1979
- Tamoxifen: A clinical trial in pre-menopausal women with metastatic carcinoma of the breast. Annals of the Royal College of Physicians and Surgeons of Canada. 12. 1979
- Tamoxifen and Metastatic Breast Cancer. ACP journal club. 89:721-721. 1978
- Tamoxifen and Hypercalcemia. ACP journal club. 89:423-423. 1978
- Tamoxifen and metastatic breast cancer. Annals of Internal Medicine. 89:721-722. 1978
- The use of oral BCG in the treatment of metastatic malignant melanoma. Pediatric Blood and Cancer. 2:173-181. 1976
- The effect of oral BCG in patients with malignant melanoma. Annals of the Royal College of Physicians and Surgeons of Canada. 8:54. 1975